Is avatrombopag safe for children aged 7 years to take?

Avatrombopag (Avatrombopag) is an oral, small molecule thrombopoietic agonist (TPO-RA) that stimulates platelet production and is used to treat chronic immune thrombocytopenia (ITP) and thrombocytopenia in patients with chronic liver disease before surgery. Although the efficacy and safety of this drug have been fully proven in adult patients, its use in children, especially children under 7 years old or around 7 years old, still needs to be carefully evaluated. At present, clinical data are relatively limited, and doctors generally decide whether it is suitable for use based on the child's specific condition, weight, and liver function status.

From a pharmacological mechanism, avatrombopag promotes the proliferation and differentiation of bone marrow megakaryocytes by activating platelet production receptors (TPOreceptors), thereby increasing peripheral blood platelet levels. This mechanism has no obvious conflict with the physiological characteristics of pediatric patients, so it can be used in children in theory. However, because children's metabolic rate, drug absorption and distribution characteristics are different from those of adults, their blood drug concentrations vary more, and they are prone to adverse reactions such as headaches, elevated liver enzymes or thrombophilia due to excessive dosage. Therefore, the dosage of medication for children should be adjusted individually and strictly in accordance with the doctor's prescription.

At present, there are clinical studies of avatrombopag on children with ITP in foreign countries, and some of the study subjects range from 6 years old to 17 years old. The results show that the drug can effectively increase platelet counts and is well tolerated by most children. The adverse reactions are similar to those of adults, mainly mild to moderate headache, fatigue or stomach discomfort. However, the study sample size is small and the observation period is limited, which still cannot fully represent the long-term drug safety. Therefore, if 7 children need to use avatrombopag, they should take the medication under the guidance of a professional hematologist, and closely monitor platelet changes and liver function indicators to ensure safety and effectiveness.

Parents should also pay attention to daily care and monitoring while their children are taking medication. Children should avoid taking other drugs that may affect liver function or platelets at the same time, such as aspirin, ibuprofen, etc.; at the same time, they should maintain a balanced diet and avoid herbal supplements or health products that may interfere with the efficacy of the drug. If any abnormality such as obvious headache, fatigue, rash or jaundice occurs, the drug should be stopped immediately and seek medical treatment. Generally speaking, avatrombopag is not absolutely contraindicated in 7 children, but it must be used with caution under strict evaluation by doctors, and attention should be paid to dynamic monitoring and individualized management during the treatment process to ensure a balance between efficacy and safety.

Reference materials:https://www.drugs.com/